Skip to main content
Clinical Trials/CTIS2023-503946-30-00
CTIS2023-503946-30-00
Recruiting
Phase 1

A randomized study to investigate central and cerebral hemodynamic effects and volume kinetics of Ringer´s Acetate compared with no intravenous fluids, during experimental hypovolemia compared with euvolemia, in healthy human volunteers.

Oslo University Hospital HF0 sites12 target enrollmentMarch 2, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Hypovolemia
Sponsor
Oslo University Hospital HF
Enrollment
12
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 2, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Oslo University Hospital HF

Eligibility Criteria

Inclusion Criteria

  • Participant must be 18 to 40 years of age inclusive, at the time of signing the informed consent, Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination and focused cardiac ultrasound, Female participants: Use of adequate birth control for women of childbearing potential, Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol

Exclusion Criteria

  • Any medical condition limiting physical exertional capacity or requiring regular medication (allergy and contraceptives excepted), Pregnancy, Breastfeeding, History of syncope (syncope of presumed vasovagal nature with known precipitating factor excepted), Any known cardiac arrhythmia, Any drug (contraceptives excepted) used on a regular basis for a chronic condition (allergy excepted)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A Randomized Pilot Study on Central Nervous System (CNS) Prophylaxiswith Liposome-Encapsulated Cytarabine (DepoCyte) in a Population of Adult Patientswith Acute Lymphoblastic Leukemia (ALL) Treated with an Updated and Lineage-TargetedMinimal Residual Disease (MRD)-Oriented Postremission Strategy. - NILG-ALL 10/072. Diagnosis of untreated ALL with B-/T-precursor phenotype or B/T-LL, either de novo or secondary to chemo-radiotherapy for other cancer.MedDRA version: 9.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disorders
EUCTR2007-006652-19-ITILG
Completed
Not Applicable
Investigating Central Neurophysiologic Correlates of Non-Motor Symptoms of Parkinson's DiseaseParkinson DiseaseAutonomic DysfunctionDepression
NCT05205772University of North Carolina, Chapel Hill30
Not yet recruiting
Not Applicable
Mental Imagery for Facial Action Control Enhancement after nerve damageower motor neurone facial nerve paralysisLower motor neurone facial nerve paralysisNeurological - Other neurological disordersPhysical Medicine / Rehabilitation - Physiotherapy
ACTRN12612001176853The University of Sydney28
Recruiting
Not Applicable
A randomized controlled trial to investigate the (cost)effectiveness of oral immunotherapy with different allergens in young children with an established food allergy.Food allergie10001708
NL-OMON51688Deventer Ziekenhuis500
Completed
Not Applicable
A randomized controlled study to examine the effects of a triple therapy with vonoprazan or rabeprazole against standard triple therapy-failed patients.Helicobacter pylori infection
JPRN-UMIN000016601Juntendo University School of Medicine, Department of Gstroenterology70